beta-funaltrexamine (beta-FNA) hydrochloride is a selective and irreversible µ opioid receptor antagonist that exhibits anti-inflammatory and neuroprotective effects. beta-Funaltrexamine hydrochloride reduces TLR4 signaling, inhibits cytokine-induced iNOS activation and neuroinflammation, and ameliorates neuronal degeneration. beta-funaltrexamine hydrochloride inhibits NF-kappaB signaling and chemokine expression in both human astrocytes and mice. beta-funaltrexamine hydrochloride can be used for research on neurodegenerative diseases, such as stroke[1][2][3].
